147 related articles for article (PubMed ID: 11893747)
1. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
[TBL] [Abstract][Full Text] [Related]
2. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
Harikumar KG; Pinon DI; Miller LJ
Biosci Rep; 2006 Apr; 26(2):89-100. PubMed ID: 16779661
[TBL] [Abstract][Full Text] [Related]
4. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor.
Harikumar KG; Hosohata K; Pinon DI; Miller LJ
J Biol Chem; 2006 Feb; 281(5):2543-50. PubMed ID: 16319066
[TBL] [Abstract][Full Text] [Related]
5. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis.
Dong M; Ding XQ; Pinon DI; Hadac EM; Oda RP; Landers JP; Miller LJ
J Biol Chem; 1999 Feb; 274(8):4778-85. PubMed ID: 9988716
[TBL] [Abstract][Full Text] [Related]
6. Use of Fluorescence Indicators in Receptor Ligands.
Harikumar KG; Miller LJ
Methods Mol Biol; 2015; 1335():115-30. PubMed ID: 26260598
[TBL] [Abstract][Full Text] [Related]
7. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
Harikumar KG; Miller LJ
J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.
Harikumar KG; Pinon DI; Miller LJ
J Biol Chem; 2006 Sep; 281(37):27072-80. PubMed ID: 16857665
[TBL] [Abstract][Full Text] [Related]
10. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
[TBL] [Abstract][Full Text] [Related]
11. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor.
Harikumar KG; Miller LJ
Pharmacol Toxicol; 2002 Dec; 91(6):286-9. PubMed ID: 12688370
[TBL] [Abstract][Full Text] [Related]
12. Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands.
Turcatti G; Zoffmann S; Lowe JA; Drozda SE; Chassaing G; Schwartz TW; Chollet A
J Biol Chem; 1997 Aug; 272(34):21167-75. PubMed ID: 9261122
[TBL] [Abstract][Full Text] [Related]
13. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
Ding XQ; Dolu V; Hadac EM; Holicky EL; Pinon DI; Lybrand TP; Miller LJ
J Biol Chem; 2001 Feb; 276(6):4236-44. PubMed ID: 11050076
[TBL] [Abstract][Full Text] [Related]
14. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
[TBL] [Abstract][Full Text] [Related]
15. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ
J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216
[TBL] [Abstract][Full Text] [Related]
16. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells.
Dunlop J; Zhang Y; Evans N
Peptides; 1997; 18(6):865-8. PubMed ID: 9285936
[TBL] [Abstract][Full Text] [Related]
17. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist.
Roettger BF; Pinon DI; Burghardt TP; Miller LJ
Am J Physiol; 1999 Mar; 276(3):C539-47. PubMed ID: 10069980
[TBL] [Abstract][Full Text] [Related]
18. Direct identification of a second distinct site of contact between cholecystokinin and its receptor.
Hadac EM; Pinon DI; Ji Z; Holicky EL; Henne RM; Lybrand TP; Miller LJ
J Biol Chem; 1998 May; 273(21):12988-93. PubMed ID: 9582333
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
Dong M; Lam PC; Pinon DI; Abagyan R; Miller LJ
Biochemistry; 2009 Jun; 48(23):5303-12. PubMed ID: 19441839
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
Harikumar KG; Puri V; Singh RD; Hanada K; Pagano RE; Miller LJ
J Biol Chem; 2005 Jan; 280(3):2176-85. PubMed ID: 15537636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
